SCHEMBL6938274

SCHEMBL6938274

CCCC(CC1(C(=O)N[C@H]2CC[C@@H](C(=O)O)CC2)CCCC1)C(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MME P08473 18/20 0.57
ALDH1A1 P00352 1/20 0.53
GAA P10253 1/20 0.53
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6938276 1.00 MME (0.57) MMEALDH1A1GAATSHR
SCHEMBL9469850 0.85 MME (0.72) MMEALDH1A1GAATSHR
SCHEMBL9469848 0.85 MME (0.72) MMEALDH1A1GAATSHR
SCHEMBL9469892 0.84 MME (0.52) MMEALDH1A1GAATSHR
SCHEMBL9469887 0.84 MME (0.52) MMEALDH1A1GAATSHR
SCHEMBL9469492 0.84 MME (0.45) MMEALDH1A1GAATSHR
SCHEMBL9469305 0.84 MME (0.45) MMEALDH1A1GAATSHR
SCHEMBL9470317 0.84 MME (0.45) MMEALDH1A1GAATSHR
SCHEMBL9470310 0.84 MME (0.45) MMEALDH1A1GAATSHR
SCHEMBL9469567 0.84 MME (0.45) MMEALDH1A1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296938-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE Pfizer Limited (GB) 2003-04-02 EP disclosed
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER, INC. 2002-05-02 US disclosed
WO-2002002513-A1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE PFIZER LIMITED (GB) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052370-A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase ENGASE, ENPEP, CPN1 MME 7/4885ALDH1A1 1319/4885GAA 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.